|
시장보고서
상품코드
1765060
세계의 골다공증 치료 시장Osteoporosis Therapeutics |
||||||
골다공증 치료 세계 시장은 2030년까지 155억 달러에 이를 전망
2024년에 131억 달러로 추정되는 골다공증 치료 세계 시장은 분석 기간인 2024-2030년 CAGR 2.9%로 성장하여 2030년에는 155억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 비스포스포네이트는 CAGR 3.1%를 나타내고, 분석 기간 종료시에는 81억 달러에 이를 것으로 예측됩니다. 부갑상선 호르몬 요법 분야의 성장률은 분석 기간중 CAGR 2.4%로 추정됩니다.
미국 시장은 53억 달러로 추정, 중국은 CAGR 5.3%로 성장 예측
미국의 골다공증 치료 시장은 2024년에 53억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 5.3%로 2030년까지 9억 10만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 2.2%와 2.5%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.6%를 보일 전망입니다.
세계의 골다공증 치료 시장 - 주요 동향과 촉진요인 정리
골다공증은 골밀도 감소와 골절 위험 증가를 특징으로 하는 만성 질환입니다. 골다공증 치료는 뼈를 강화하고, 뼈 손실을 최소화하며, 골절 위험을 감소시키는 것을 목표로 하며, 주로 약리학적 치료제를 사용합니다. 이러한 치료법에는 골 흡수를 억제하는 비스포스포네이트 제제, 에스트로겐의 골밀도에 대한 유익한 효과를 호르몬의 잠재적 위험 없이 재현하는 선택적 에스트로겐 수용체 조절제(SERM), 뼈 성장을 자극하는 부갑상선 호르몬 관련 단백질 등이 있습니다. 최근에는 골 흡수에 관여하는 중요한 단백질을 표적으로 억제하는 데노삽과 같은 생물학적 제제를 이용한 치료도 시행되고 있습니다. 치료법의 선택은 환자 고유의 위험인자, 골밀도 감소 정도, 다른 병력 유무 등 다양한 요인에 따라 달라질 수 있습니다. 또한, 칼슘과 비타민 D 보충제는 뼈 건강에 중요한 요소이기 때문에 뼈의 강도를 높이기 위해 이러한 치료와 병행하여 권장되는 경우가 많습니다.
골다공증의 관리와 예방에는 약물 치료와 더불어 생활습관 개선이 중요한 역할을 합니다. 골밀도와 골강도를 향상시키기 위해서는 규칙적인 체중부하 운동과 근력 강화 운동이 권장됩니다. 또한, 뼈에 좋은 영양소를 충분히 섭취할 수 있도록 식단을 조절하고, 금연과 음주량을 줄이는 등 생활습관을 개선하는 것도 뼈 건강에 좋은 영향을 미칩니다. 골다공증 치료에 있어 기술의 역할도 확대되고 있으며, 골밀도 측정법의 개발로 골밀도 모니터링의 정확성과 편의성이 향상되고 있습니다. 원격 의료 및 모바일 건강 용도는 환자와 의료 서비스 제공업체에게 질병 관리, 약물 순응도 향상, 생활습관 개입을 통한 환자 경과 추적에 더 나은 도구를 제공합니다. 이러한 기술적 진보는 골다공증 관리에 대한 보다 적극적이고 개별화된 접근 방식을 지원하며, 치료 및 예방 전략을 개별 환자의 요구에 더 가깝게 조정할 수 있도록 돕습니다.
골다공증 치료 시장의 성장은 전 세계 노인 인구 증가, 골다공증 유병률 증가, 치료 옵션의 발전, 질병에 대한 인식 증가 등 여러 요인에 의해 주도되고 있습니다. 세계 인구의 고령화에 따라 골다공증과 이로 인한 골절 발생률은 증가할 것으로 예상되며, 효과적인 치료 솔루션에 대한 수요가 증가하고 있습니다. 제약 및 바이오테크놀러지의 발달로 부작용이 적고 효과적인 신약이 개발되어 환자 결과와 순응도를 개선하고 있습니다. 또한, 진단 기술과 스크리닝 방법의 개선에 힘입어 조기 진단과 예방에 대한 중요성이 강조되고 있으며, 이는 시장을 더욱 자극하고 있습니다. 골다공증과 삶의 질에 미치는 영향에 대한 대중과 의료진의 인식이 높아진 것도 신흥국의 의료 인프라 및 보험 적용 범위 확대와 함께 시장을 견인하고 있습니다. 이러한 역학으로 인해 골다공증의 효과적인 관리에 대한 시급한 요구와 치료법 및 제품의 지속적인 개선으로 골다공증 치료제 시장은 지속적으로 확대될 것으로 보입니다.
부문
약제 클래스별(비스포스포네이트, 부갑상선 호르몬 요법, 칼시토닌, 선택적 에스트로겐 억제제(SERM), 랭크 리간드 억제제), 투여 경로별(경구제, 주사제, 기타 투여 경로)
조사 대상 기업 예
- Amgen, Inc.
- Asahi Kasei Pharma Corporation
- Bone Biologics Corp.
- Novartis AG
- Pfizer, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Teijin Ltd.
- Transcenta
- Uni-Bio Science Group Ltd.
- Viking Therapeutics
- Zydus Lifesciences Limited
AI 통합
당사는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 주요 요약
- 시장 개요
- 주요 기업
- 시장 동향과 촉진요인
- 세계 시장 전망
제3장 시장 분석
- 미국
- 캐나다
- 일본
- 중국
- 유럽
- 프랑스
- 독일
- 이탈리아
- 영국
- 기타 유럽
- 아시아태평양
- 기타 지역
제4장 경쟁
LSH 25.07.15Global Osteoporosis Therapeutics Market to Reach US$15.5 Billion by 2030
The global market for Osteoporosis Therapeutics estimated at US$13.1 Billion in the year 2024, is expected to reach US$15.5 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end of the analysis period. Growth in the Parathyroid Hormone Therapy segment is estimated at 2.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$5.3 Billion While China is Forecast to Grow at 5.3% CAGR
The Osteoporosis Therapeutics market in the U.S. is estimated at US$5.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$900.1 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.
Global Osteoporosis Therapeutics Market - Key Trends & Drivers Summarized
Osteoporosis is a chronic condition characterized by a decrease in bone density and an increased risk of fractures. Therapeutics for osteoporosis aim to strengthen bone, minimize bone loss, and reduce the risk of fracture, primarily through the use of pharmacological treatments. These treatments include bisphosphonates, which inhibit bone resorption; selective estrogen receptor modulators (SERMs), which replicate estrogen's beneficial effects on bone density without some of the hormone's potential risks; and parathyroid hormone-related proteins, which can stimulate bone growth. More recently, treatments have included biological agents such as denosumab, which targets and inhibits a key protein involved in bone resorption. The choice of treatment depends on various factors, including the patient's specific risk factors, the severity of bone density loss, and the presence of other medical conditions. Additionally, calcium and vitamin D supplements are often recommended alongside these treatments to enhance bone strength, as both are critical components of bone health.
In addition to pharmacotherapy, lifestyle modifications play a crucial role in managing and preventing osteoporosis. Regular weight-bearing and muscle-strengthening exercises are recommended to help improve bone density and strength. Moreover, dietary adjustments to ensure adequate intake of bone-healthy nutrients, and lifestyle changes such as smoking cessation and reducing alcohol consumption, can also have a positive impact on bone health. The role of technology in osteoporosis therapeutics has also been expanding, with developments in bone densitometry improving the accuracy and ease of monitoring bone density. Telemedicine and mobile health applications provide patients and healthcare providers with better tools for managing the disease, improving medication adherence, and tracking patient progress with lifestyle interventions. These technological advancements support a more proactive and personalized approach to osteoporosis management, aligning treatment and preventive strategies more closely with individual patient needs.
The growth in the osteoporosis therapeutics market is driven by several factors, including the increasing global elderly population, rising prevalence of osteoporosis, advancements in therapeutic options, and growing awareness of the disease. As the global population ages, the incidence of osteoporosis and resultant fractures is expected to rise, driving demand for effective treatment solutions. Advances in pharmaceuticals and biotechnology have led to the development of newer, more effective drugs with fewer side effects, enhancing patient outcomes and compliance. Additionally, there is a growing emphasis on early diagnosis and prevention, supported by improvements in diagnostic technologies and screening practices, which further stimulate the market. Increased public and medical community awareness about osteoporosis and its impact on quality of life has also helped to drive the market, as has the expansion of healthcare infrastructure and insurance coverage in emerging economies. These dynamics suggest that the osteoporosis therapeutics market will continue to expand, driven by both an urgent need for effective management of osteoporosis and ongoing improvements in therapeutic practices and products.
SCOPE OF STUDY:
The report analyzes the Osteoporosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), and Rank Ligand Inhibitors); Route of Administration (Oral, Injectables, and Other Routes of Administration)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 53 Featured) -
- Amgen, Inc.
- Asahi Kasei Pharma Corporation
- Bone Biologics Corp.
- Novartis AG
- Pfizer, Inc.
- Taisho Pharmaceutical Co., Ltd.
- Teijin Ltd.
- Transcenta
- Uni-Bio Science Group Ltd.
- Viking Therapeutics
- Zydus Lifesciences Limited
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Tariff Impact on Global Supply Chain Patterns
- A Prelude to Osteoporosis
- Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market
- Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth
- Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis
- Approved Drugs for Treatment of Osteoporosis
- Select Recent Osteoporosis Drug Approvals
- Osteoporosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics
- % of Women Affected by Osteoporosis
- Osteoporosis - Factsheet
- Osteoporosis in Men
- Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains
- Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025
- Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth
- Changing Lifestyle Impacting Bone Health
- Recommended Daily Intake of Calcium and Vitamin D
- Increasing Awareness Related to Osteoporosis Care
- New Product Launches Foster Market Growth
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Osteoporosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 12: World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: World 16-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 15: World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: World 16-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 18: World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: World 16-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
- TABLE 26: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 27: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: World 16-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 29: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: USA 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 32: USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: USA 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- CANADA
- TABLE 35: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: Canada 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 38: Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: Canada 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- JAPAN
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 41: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: Japan 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 44: Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: Japan 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- CHINA
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 47: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: China 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 50: China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 51: China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: China 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- EUROPE
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 53: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 54: Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: Europe 16-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 56: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 59: Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- FRANCE
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 62: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: France 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 65: France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: France 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- GERMANY
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 68: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 69: Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: Germany 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 71: Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: Germany 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- ITALY
- TABLE 74: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: Italy 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 77: Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: Italy 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 80: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: UK 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 83: UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: UK 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 87: Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Rest of Europe 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Asia-Pacific 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
- REST OF WORLD
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Rest of World Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Revenues for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2014, 2025 & 2030
- TABLE 101: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: Rest of World Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: Rest of World 16-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Revenues for Oral, Injectables and Other Routes of Administration for the Years 2014, 2025 & 2030
